C3J Therapeutics Bolsters Antimicrobial R&D Program; Acquires Engineered Bacteriophage Assets from Synthetic … – Business Wire (press release)
|
C3J Therapeutics Bolsters Antimicrobial R&D Program; Acquires Engineered Bacteriophage Assets from Synthetic …
Business Wire (press release) LOS ANGELES & LA JOLLA, Calif.–(BUSINESS WIRE)–C3J Therapeutics, Inc., (C3J) a private biotechnology company focused on the development of novel targeted antimicrobials, and Synthetic Genomics, Inc., (SGI) a leader in designing and programming … |
